Prostate cancer
Conditions
Interventions
Taking GTE tablet with hormonal therapy
hormonal therapy alone
Sponsors
The University of Tsukuba Graduate Schools
Tsukuba prostate cancer prevention study group
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: a) clinical stage C or D b) any age c) performance status 0-3 d) both of beginning hormonal therapy (fresh cases)and under hormonal theprapy(under treatment cases)are included e) The PSA value of under treatment cases were normalized (less than 4 ng/ml) within 6 months after hormonal therapy, and the PSA value was stable. f) The PSA value before hormonal therapy was out of normal range. The measurement of PSA value is decided as Tandem-R. The value with other measurement is converted into Tandem-R. g) The treatment before hormonal therapy is not unrelated. h) Acquired informed consent with writing
Exclusion criteria
Exclusion criteria: a) Patients who have active double cancer. b) Patients who have digestive tract ulcer and a critical liver, kidney, and heart disease. c) Patients who experienced palpitation and heartburn with coffee or tea. d) Patients who have abnormality in a blood cells or biochemical examination of blood classified into two or more grade of NCI toxicity criteria e) Patients considered not to have a six months prognosis. f) Patients who are judged to be unsuitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to hormone refractory | — |
Secondary
| Measure | Time frame |
|---|---|
| Survival time (disease specific survival, overall survival) and adverse event | — |
Countries
Japan
Contacts
Public ContactNaoto Miyanaga
The University of Tsukuba Graduate Schools Department of Urology, Institute of Clinical Medicine
Outcome results
None listed